EZH2 and epithelioid sarcoma: We used tazemetostat (Knutson et al, 2014), a potent and selective competitive inhibitor of EZH2 approved for treatment of epithelioid sarcoma, to explore the antiviral potential of stand‐alone EZH2 inhibition against SARS‐CoV‐2.